Eric Dian

Richard Conway, a vasculitis specialist, discusses pivotal findings from ACR 2024. Peter Nash delves into the role of JAK inhibitors, while Janet Pope reviews treatment strategies for polymyalgia rheumatica and giant cell arteritis. Eric Dian analyzes intriguing oral abstracts on rheumatoid arthritis, and David Liu emphasizes cardiovascular risks associated with treatments. They explore the safety of JAKs, advances in managing RA during COVID-19, and the efficacy of new therapies for PMR and GCA, showcasing innovative strategies for improving patient outcomes.

Rinaldi Day, a clinical fellow from London, and Eric Dian, a rheumatologist from Summit, New Jersey, dive into the cutting-edge insights from the ACR Annual Meeting. They discuss a pivotal study linking steroid use to cardiovascular events in rheumatoid arthritis and share findings on optimizing treatment for giant cell arteritis. The conversation touches on racial biases in lung function calculations and the disparities in medication outcomes for connective tissue diseases, highlighting the urgent need for improved management strategies and monitoring.